DalCor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

DalCor Pharmaceuticals Inc (DalCor Pharmaceuticals) researches and develops precision medicine for patients suffering from cardiovascular diseases. The company is engaged in development of Dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor which is intended to reduce cardiovascular events in a genetically distinct subset of patients. DalCor Pharmaceuticals is also engaged in the development of dal- GenE which is used for the treatment of cardiovascular death, myocardial infarction (heart attack) and stroke. The company operates in Canada, the US, Switzerland and the UK. DalCor Pharmaceuticals is headquartered in Montreal, Quebec, Canada.

DalCor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
DalCor Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
DalCor Pharma Raises USD78 Million in Series B Financing 11
DalCor Pharma Raises USD36.1 Million in Series A Financing 12
Private Equity 13
Fonds de solidarite FTQ Invests USD7.5 Million in DalCor Pharma 13
Licensing Agreements 14
Roche Enters into Licensing Agreement with Dalcor Pharma 14
Dalcor Pharma Enters into Licensing Agreement with Montreal Heart Institute Research Centre 15
DalCor Pharmaceuticals Inc - Key Competitors 16
DalCor Pharmaceuticals Inc - Key Employees 17
DalCor Pharmaceuticals Inc - Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Corporate Communications 19
Apr 09, 2018: DalCor Pharmaceuticals Names Dr. Fouzia Laghrissi-Thode As Chief Executive Officer 19
Nov 15, 2017: DalCor Pharmaceuticals Appoints Dr. Fouzia Laghrissi-Thode to the Board of Directors 20
Clinical Trials 21
Mar 07, 2017: DalCors Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule 21
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List Of Tables


DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DalCor Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
DalCor Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
DalCor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
DalCor Pharma Raises USD78 Million in Series B Financing 11
DalCor Pharma Raises USD36.1 Million in Series A Financing 12
Fonds de solidarite FTQ Invests USD7.5 Million in DalCor Pharma 13
Roche Enters into Licensing Agreement with Dalcor Pharma 14
Dalcor Pharma Enters into Licensing Agreement with Montreal Heart Institute Research Centre 15
DalCor Pharmaceuticals Inc, Key Competitors 16
DalCor Pharmaceuticals Inc, Key Employees 17
DalCor Pharmaceuticals Inc, Other Locations 18

List Of Figures


Xinjiang Goldwind Science & Technology Co Ltd, Performance Chart (2013 - 2017) 31
Xinjiang Goldwind Science & Technology Co Ltd, Ratio Charts 33
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals By Year, 2012 to YTD 2018 34
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals by Type, 2012 to YTD 2018 35

DalCor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DalCor Pharmaceuticals Inc (DalCor Pharmaceuticals) researches and develops precision medicine for patients suffering from cardiovascular diseases. The company is engaged in development of Dalcetrapib, a cholesterol ester transfer protein (CETP)

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available